CSL Limited
ASX:CSL
$ 285.96
$-4.27 (-1.50%)
$ 285.96
$-4.27 (-1.50%)
Real-time: 03/27/2024 12:15

About CSL

CSL Limited is a public company which is a parent company of the CSL Group. CSL business activities are carried out through its Human Health, JRH Biosciences, Animal Health and ZLB Plasma Services operations. CSL limited develops, manufactures and markets pharmaceutical products of biological origin. The company’s business is health care: Life-saving products derived from human plasma; Pharmaceuticals and diagnostics essential to health; Cell culture reagents for the pharmaceutical industry; and Veterinary vaccines and diagnostics to protect livestock and companion animals. The company’s Human Health business includes the operations of ZLB Bioplasma, CSL Bioplasma, CSL Pharmaceutical, and its global new product development activities. CSL share price history

JRH Biosciences Pty, Ltd, based in Melbourne, is a subsidiary of CSL Limited that processes Australian animal serum used to produce cell culture media.

CSL (New Zealand) Limited, based in Auckland, is a subsidiary of CSL Limited and is the New Zealand marketing arm for Australian Bioplasma, Pharmaceutical and Animal Health business operations. CSL (New Zealand) Limited also manufactures veterinary viral vaccines at a plant in Upper Hutt, near Wellington.

Iscotec AB, a Swedish company, is a subsidiary of CSL Limited that has technology to enhance the immune response to vaccines.

Cervax Pty, Ltd is a subsidiary of CSL Limited and is a company formed to undertake a specific research and development project. Cervax is 74% owned by CSL.

CSL International Pty, Ltd is a subsidiary of CSL Limited and the holding company for the international operations of the CSL Group. CSL share price history

CSL Denmark ApS is a subsidiary of CSL International Pty Ltd and the holding company for the European subsidiaries of the Group.

CSL US, Inc. is a subsidiary of CSL International Pty Ltd and the holding company for the US operations of the CSL Group.

CSL Finance Pty, Ltd is a subsidiary of CSL International Pty Ltd through which the CSL Group raises debt funding.

JRH Biosciences, Inc. is a subsidiary of CSL US, Inc. Based in Kansas in the US, it is one of the manufacturers of specialised cell culture media in the world. JRH Biosciences, Inc. has manufacturing sites in Kansas and Pennsylvania.

Biocor Animal Health Inc. is a subsidiary of CSL US, Inc. Based in the US at Omaha in Nebraska, Biocor manufactures and markets veterinary vaccines and is operationally part of CSL's Animal Health Group.

ZLB Bioplasma, Inc., a Los Angeles based subsidiary of CSL US, Inc., is operationally part of ZLB Bioplasma AG. In the US, ZLB Bioplasma, Inc. markets and distributes plasma-derived products and operates ZLB Plasma Services, a Florida based plasma collection business.

ZLB Bioplasma AG., based in Bern, Switzerland, is a subsidiary of CSL Denmark ApS. ZLB Bioplasma AG manufactures plasmaderived products and has major markets in the US and Europe.

ZLB Bioplasma Belgium sprl, a subsidiary of CSL Denmark ApS, is a sales and marketing company for plasma products manufactured by ZLB Bioplasma AG.

ZLB Bioplasma Italy srl, a subsidiary of CSL Denmark ApS, is a sales and marketing company for plasma products manufactured by ZLB Bioplasma AG.

CSL UK Holdings Limited, a subsidiary of CSL Denmark ApS, is the holding company for the United Kingdom operations of the CSL Group.

JRH Biosciences Limited, based in Andover in the United Kingdom, is a subsidiary of CSL UK Holdings Limited and is the European sales and marketing arm of JRH Biosciences Inc.

ZLB Bioplasma UK Limited, a subsidiary of CSL UK Holdings Limited, is a sales and marketing company for plasma products manufactured by ZLB Bioplasma AG.

ZLB GmbH, a German subsidiary of ZLB Bioplasma AG, is a sales and marketing company for plasma products manufactured by ZLB Bioplasma AG.

ZLB Bioplasma AG is one of the manufacturers of plasma products in the world with major markets in the USA and Europe. Major plasma products marketed by zlb bioplasma are Carimune NF, Carimune, Redimune, Sandoglobulin, Panglobulin, Rhophylac and Albumin.

CSL Bioplasma is one of the manufacturers of plasma products in the Southern Hemisphere with a state-of-the-art facility in Melbourne that uses chromatographic production technology. Major plasma products marketed by csl bioplasma are AHF (HP), Biostate, MonoFix - VF, Intragam P, VI-IMIG, Rh(D) Immunoglobulin, Albumex, ABO Monoclonal Reagents and Reagent Red Blood Cells.

CSL Pharmaceutical manufactures and markets biological products for human use. The company’s activities range from funding early stage research in universities and research institutes to selling products worldwide through major international organisations. Major pharmaceutical products marketed by CSL are Fluvax, Pneumovax* 23, Menjugate, ADT, Tet-Tox, H-B-VAX II, PedvaxHIB, Vaqta, Varivax* Refrigerated, Comvax, Q-Vax, M-M-R II, Flopen, Moxacin, Fucidin, BenPen, Tramal, Flomax, Antivenoms, Cervidil, Modavigil, EpiPen, Daivonex and Advantan.

JRH Biosciences develops, manufactures and markets cell culture reagents, including dry powder media, liquid media and sera used in the manufacture of vaccines, biopharmaceuticals and gene therapy products.

BIOTECHNOLOGY SERVICES USED IN CELL CULTURE APPLICATIONS

imMEDIAte Advantage: Program for quick delivery of small volumes of customised media, either in liquid or dry powder form, preferred by scientists in research and product development.

BioEaze: Sterile disposable bags, components and bioprocessing systems designed to address specific pharmaceutical and biotechnology applications.

Bulk Liquid Media System: Customised liquid media handling systems designed to facilitate raw material transfer in cell culture laboratories.

Media Development and Optimisation: Development of media formulations specific to customer cell lines and applications, focussed on improving productivity and efficiencies.

Technical Services: Regulatory support to meet customer and government requirements for licensing issues; customer support on product applications and cell culture techniques; and product support focussing on technology transfer.

Analytical Services: Biochemical analyses that aids cell culture product development and optimisation.

Animal Health develops, manufactures and markets vaccines for the prevention of disease in livestock (sheep, cattle and pigs) and companion animals (horses, dogs and cats), and a range of diagnostic products. Major animal health products marketed by CSL are Glanvac, Ultravac 7 in 1, Scabigard, Canvac, Bronchicine Cae, Fevac, Rhinopan, Equivac, Longrange, Ultravac 5 in 1, Gudair, Surround, HerdVac, Improvac, Leptoshield, Bovigam and Parachek.

Significant Events

Arana Therapeutics Limited has completed a collaborative project with its pharmaceutical partner CSL, Ltd. Arana utilised its superhumanisation technology to develop humanised versions of lead antibodies from the CSL pharmaceutical pipeline.

CSL, Ltd. and Vivalis SA have a research license and option for a commercial agreement to assess the EBx platform. The purpose of the agreement is to test the EB66 cell line for the development and manufacturing of a therapeutic protein candidate.

The company has a collaboration with MuriGen Therapeutics Pty., Ltd. for the development of a new class of drugs that target arthritis and other inflammatory diseases.

On June 19, 2009, Phosphagenics Ltd. has signed a research and option agreement with CSL Ltd. to evaluate Phosphagenics' proprietary TPM delivery technology to deliver large proteins.

On September 4, 2009, ZTE Corp. formed a partnership with CSL Ltd. to build a 4G commercial trial network in Hong Kong. The two companies would jointly expand CSL's next generation network capabilities with the roll-out of a Universal Mobile Telecommunications System and the building of a 4G or Long Term Evolution network in Hong Kong.

On December 10, 2009, CSL Ltd. announced that it has inked a collaborative agreement with Sanofi Pasteur SA for the development of a vaccine against severe gum disease periodontitis.

Country
Founded:
1916
IPO Date:
06/02/1994
ISIN Number:
I_AU000000CSL8

Contact Details

Address:
655 Elizabeth Street Melbourne, Victoria, 3000, Australia
Phone Number
61 3 9389 1911

Key Executives

CEO:
McKenzie, Paul
CFO
Linton, Joy
COO:
Data Unavailable